Evidence map›Paper›PMID 35898695›Full record

ArticleLeukemia research reports2022

Severe acute heart failure during or following cytokine release syndrome after CAR T-cell therapy.

Kyoko Yoshihara, Yoshiyuki Orihara, Tokiko Hoshiyama, Hiroya Tamaki, Isamu Sunayama, Ikuo Matsuda, Akinori Nishikawa, Tomoko Kumamoto, Mami Samori, Nobuto Utsunomiya and 6 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia research reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Kyoko YoshiharaDepartment of Hematology, Hyogo Medical University Hospital, Hyogo, Japan.
Yoshiyuki OriharaDepartment of Cardiovascular and Renal Medicine, Hyogo Medical University Hospital, Hyogo, Japan.
Tokiko HoshiyamaDepartment of Hematology, Hyogo Medical University Hospital, Hyogo, Japan.
Hiroya TamakiDepartment of Hematology, Hyogo Medical University Hospital, Hyogo, Japan.
Isamu SunayamaDepartment of Cardiovascular and Renal Medicine, Hyogo Medical University Hospital, Hyogo, Japan.
Ikuo MatsudaDepartment of Surgical Pathology, Hyogo Medical University Hospital, Hyogo, Japan.
Akinori NishikawaDepartment of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.
Tomoko KumamotoDepartment of Hematology, Hyogo Medical University Hospital, Hyogo, Japan.
Mami SamoriDepartment of Hematology, Hyogo Medical University Hospital, Hyogo, Japan.
Nobuto UtsunomiyaDepartment of Hematology, Hyogo Medical University Hospital, Hyogo, Japan.
Kyung-Duk MinDepartment of Cardiovascular and Renal Medicine, Hyogo Medical University Hospital, Hyogo, Japan.
Masanori AsakuraDepartment of Cardiovascular and Renal Medicine, Hyogo Medical University Hospital, Hyogo, Japan.
Seiichi HirotaDepartment of Surgical Pathology, Hyogo Medical University Hospital, Hyogo, Japan.
Masaharu IshiharaDepartment of Cardiovascular and Renal Medicine, Hyogo Medical University Hospital, Hyogo, Japan.
Satoshi HigasaDepartment of Hematology, Hyogo Medical University Hospital, Hyogo, Japan.
Satoshi YoshiharaDepartment of Hematology, Hyogo Medical University Hospital, Hyogo, Japan.
Hyogo Medical University · JPWakayama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although cardiac dysfunction after chimeric antigen receptor (CAR) T-cell therapy has been increasingly reported, the underlying dynamics and pathogenesis are not well documented. Herein, we describe the clinical presentation and treatment for two patients who developed severe acute heart failure after CAR T-cell therapy. Both cases shared several common characteristics, including the bone marrow involvement at the time of CAR T-cell therapy and early onset of cytokine release syndrome (CRS) with fever developing on the day of CAR T-cell infusion. Patients with early onset and/or severe CRS should be carefully monitored for the possibility of heart failure.

Indexed as

Acute heart failureCAR T-cell therapyCytokine release syndrome

Identifiers

PMID35898695
PMCPMC9310108
OpenAlexW4285405301

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.